846 related articles for article (PubMed ID: 35164569)
1. The Human Nose Organoid Respiratory Virus Model: an
Rajan A; Weaver AM; Aloisio GM; Jelinski J; Johnson HL; Venable SF; McBride T; Aideyan L; Piedra FA; Ye X; Melicoff-Portillo E; Yerramilli MRK; Zeng XL; Mancini MA; Stossi F; Maresso AW; Kotkar SA; Estes MK; Blutt S; Avadhanula V; Piedra PA
mBio; 2021 Feb; 13(1):e0351121. PubMed ID: 35164569
[TBL] [Abstract][Full Text] [Related]
2. The human nose organoid respiratory virus model: an ex-vivo human challenge model to study RSV and SARS-CoV-2 pathogenesis and evaluate therapeutics.
Rajan A; Weaver AM; Aloisio GM; Jelinski J; Johnson HL; Venable SF; McBride T; Aideyan L; Piedra FA; Ye X; Melicoff-Portillo E; Yerramilli MRK; Zeng XL; Mancini MA; Stossi F; Maresso AW; Kotkar SA; Estes MK; Blutt S; Avadhanula V; Piedra PA
bioRxiv; 2021 Jul; ():. PubMed ID: 34341793
[TBL] [Abstract][Full Text] [Related]
3. Human Respiratory Syncytial Virus Subgroup A and B Infections in Nasal, Bronchial, Small-Airway, and Organoid-Derived Respiratory Cultures.
Rijsbergen LC; Lamers MM; Comvalius AD; Koutstaal RW; Schipper D; Duprex WP; Haagmans BL; de Vries RD; de Swart RL
mSphere; 2021 May; 6(3):. PubMed ID: 33980679
[TBL] [Abstract][Full Text] [Related]
4. Human Organotypic Airway and Lung Organoid Cells of Bronchiolar and Alveolar Differentiation Are Permissive to Infection by Influenza and SARS-CoV-2 Respiratory Virus.
Ekanger CT; Zhou F; Bohan D; Lotsberg ML; Ramnefjell M; Hoareau L; Røsland GV; Lu N; Aanerud M; Gärtner F; Salminen PR; Bentsen M; Halvorsen T; Ræder H; Akslen LA; Langeland N; Cox R; Maury W; Stuhr LEB; Lorens JB; Engelsen AST
Front Cell Infect Microbiol; 2022; 12():841447. PubMed ID: 35360113
[TBL] [Abstract][Full Text] [Related]
5. Respiratory Syncytial Virus and Human Metapneumovirus Infections in Three-Dimensional Human Airway Tissues Expose an Interesting Dichotomy in Viral Replication, Spread, and Inhibition by Neutralizing Antibodies.
Kinder JT; Moncman CL; Barrett C; Jin H; Kallewaard N; Dutch RE
J Virol; 2020 Sep; 94(20):. PubMed ID: 32759319
[TBL] [Abstract][Full Text] [Related]
6. Human Nasal Organoids Model SARS-CoV-2 Upper Respiratory Infection and Recapitulate the Differential Infectivity of Emerging Variants.
Chiu MC; Li C; Liu X; Song W; Wan Z; Yu Y; Huang J; Xiao D; Chu H; Cai JP; To KK; Yuen KY; Zhou J
mBio; 2022 Aug; 13(4):e0194422. PubMed ID: 35938726
[TBL] [Abstract][Full Text] [Related]
7. Air-Liquid-Interface Differentiated Human Nose Epithelium: A Robust Primary Tissue Culture Model of SARS-CoV-2 Infection.
Tran BM; Grimley SL; McAuley JL; Hachani A; Earnest L; Wong SL; Caly L; Druce J; Purcell DFJ; Jackson DC; Catton M; Nowell CJ; Leonie L; Deliyannis G; Waters SA; Torresi J; Vincan E
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055020
[TBL] [Abstract][Full Text] [Related]
8. Development of bioluminescence imaging of respiratory syncytial virus (RSV) in virus-infected live mice and its use for evaluation of therapeutics and vaccines.
Fuentes S; Arenas D; Moore MM; Golding H; Khurana S
Vaccine; 2017 Jan; 35(4):694-702. PubMed ID: 27989627
[TBL] [Abstract][Full Text] [Related]
9. Induction and Antagonism of Antiviral Responses in Respiratory Syncytial Virus-Infected Pediatric Airway Epithelium.
Villenave R; Broadbent L; Douglas I; Lyons JD; Coyle PV; Teng MN; Tripp RA; Heaney LG; Shields MD; Power UF
J Virol; 2015 Dec; 89(24):12309-18. PubMed ID: 26423940
[TBL] [Abstract][Full Text] [Related]
10. Influenza A and Respiratory Syncytial Virus Trigger a Cellular Response That Blocks Severe Acute Respiratory Syndrome Virus 2 Infection in the Respiratory Tract.
Dee K; Schultz V; Haney J; Bissett LA; Magill C; Murcia PR
J Infect Dis; 2023 Jun; 227(12):1396-1406. PubMed ID: 36550077
[TBL] [Abstract][Full Text] [Related]
11. Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures.
Broadbent L; Parke HG; Ferguson LJ; Millar A; Shields MD; Detalle L; Power UF
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767728
[TBL] [Abstract][Full Text] [Related]
12. Respiratory syncytial virus bronchiolitis in congenital diaphragmatic hernia: A systematic review of prevalence rates and palivizumab prophylaxis.
Lewis L; Sinha I; Losty PD
Pediatr Pulmonol; 2022 Jan; 57(1):239-244. PubMed ID: 34617409
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil-Airway Epithelial Interactions Result in Increased Epithelial Damage and Viral Clearance during Respiratory Syncytial Virus Infection.
Deng Y; Herbert JA; Robinson E; Ren L; Smyth RL; Smith CM
J Virol; 2020 Jun; 94(13):. PubMed ID: 32295918
[TBL] [Abstract][Full Text] [Related]
14. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Modeling of SARS-CoV-2 Infection of
Hao S; Ning K; Kuz CA; Vorhies K; Yan Z; Qiu J
mBio; 2020 Nov; 11(6):. PubMed ID: 33158999
[TBL] [Abstract][Full Text] [Related]
16. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
[TBL] [Abstract][Full Text] [Related]
17. Authentic Modeling of Human Respiratory Virus Infection in Human Pluripotent Stem Cell-Derived Lung Organoids.
Porotto M; Ferren M; Chen YW; Siu Y; Makhsous N; Rima B; Briese T; Greninger AL; Snoeck HW; Moscona A
mBio; 2019 May; 10(3):. PubMed ID: 31064833
[TBL] [Abstract][Full Text] [Related]
18. Respiratory Syncytial Virus Protects Bystander Cells against Influenza A Virus Infection by Triggering Secretion of Type I and Type III Interferons.
Czerkies M; Kochańczyk M; Korwek Z; Prus W; Lipniacki T
J Virol; 2022 Nov; 96(22):e0134122. PubMed ID: 36326278
[TBL] [Abstract][Full Text] [Related]
19. 4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication.
Sourimant J; Lieber CM; Aggarwal M; Cox RM; Wolf JD; Yoon JJ; Toots M; Ye C; Sticher Z; Kolykhalov AA; Martinez-Sobrido L; Bluemling GR; Natchus MG; Painter GR; Plemper RK
Science; 2022 Jan; 375(6577):161-167. PubMed ID: 34855509
[TBL] [Abstract][Full Text] [Related]
20. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
